Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$3.47 +11.2%	$2.38	$1.89 ▼ $3.68	$931.08M	0.36	3.23 million shs	8.62 million shs
ACAD ACADIA Pharmaceuticals	$22.95 +0.7%	$18.50	$13.40 ▼ $25.23	$3.82B	0.65	1.94 million shs	2.41 million shs
MRUS Merus	$52.59 -0.9%	$47.32	$33.19 ▼ $62.98	$3.67B	1.04	755,854 shs	1.96 million shs
RNA Avidity Biosciences	$29.32 -0.1%	$30.28	$21.51 ▼ $56.00	$3.54B	0.95	1.41 million shs	990,714 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	+11.22%	+7.43%	+71.78%	+45.80%	+14.90%
ACAD ACADIA Pharmaceuticals	+0.66%	+2.91%	+4.37%	+33.59%	+54.34%
MRUS Merus	-0.92%	-4.47%	+27.15%	+8.86%	-3.04%
RNA Avidity Biosciences	-0.14%	-8.40%	-2.98%	-4.90%	-23.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	2.7208 of 5 stars	3.4	1.0	3.2	3.3	0.6
ACAD ACADIA Pharmaceuticals	3.8372 of 5 stars	3.3	1.0	3.3	4.2	2.5
MRUS Merus	3.3639 of 5 stars	4.6	3.0	2.9	1.7	0.0
RNA Avidity Biosciences	2.021 of 5 stars	4.5	0.0	2.0	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.75	Moderate Buy	$8.33	140.15% Upside
ACAD ACADIA Pharmaceuticals	2.69	Moderate Buy	$26.79	16.71% Upside
MRUS Merus	3.14	Buy	$84.64	60.94% Upside
RNA Avidity Biosciences	3.06	Buy	$66.56	127.02% Upside

Current Analyst Ratings Breakdown

Latest ABCL, ACAD, MRUS, and RNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	RNA Avidity Biosciences	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00
6/11/2025	RNA Avidity Biosciences	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$65.00
6/10/2025	RNA Avidity Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$70.00 ➝ $75.00
6/10/2025	RNA Avidity Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$57.00 ➝ $59.00
6/10/2025	RNA Avidity Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$57.00 ➝ $59.00
6/9/2025	RNA Avidity Biosciences	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$48.00 ➝ $54.00
6/9/2025	RNA Avidity Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $75.00
6/6/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $30.00
6/5/2025	ACAD ACADIA Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/5/2025	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Hold	$18.00 ➝ $23.00
5/23/2025	MRUS Merus	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$28.83M	35.92	N/A	N/A	$3.58 per share	0.97
ACAD ACADIA Pharmaceuticals	$957.80M	4.01	$0.71 per share	32.35	$4.40 per share	5.22
MRUS Merus	$36.13M	100.74	N/A	N/A	$9.46 per share	5.56
RNA Avidity Biosciences	$10.90M	324.19	N/A	N/A	$11.94 per share	2.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$162.86M	-$0.56	N/A	N/A	N/A	-737.56%	-15.98%	-12.38%	8/5/2025 (Estimated)
ACAD ACADIA Pharmaceuticals	$226.45M	$1.37	16.75	30.20	4.87	22.97%	17.46%	10.75%	8/5/2025 (Estimated)
MRUS Merus	-$215.33M	-$4.08	N/A	N/A	N/A	-506.73%	-35.99%	-29.83%	7/30/2025 (Estimated)
RNA Avidity Biosciences	-$322.30M	-$3.00	N/A	N/A	N/A	-4,136.00%	-26.96%	-24.57%	8/8/2025 (Estimated)

Latest ABCL, ACAD, MRUS, and RNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/8/2025	Q1 2025	ABCL AbCellera Biologics	-$0.17	-$0.15	+$0.02	-$0.15	$7.12 million	$4.24 million
5/8/2025	Q1 2025	RNA Avidity Biosciences	-$0.88	-$0.90	-$0.02	-$0.90	$2.63 million	$1.60 million
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	10.15	10.15
ACAD ACADIA Pharmaceuticals	N/A	2.88	2.80
MRUS Merus	N/A	5.86	5.86
RNA Avidity Biosciences	N/A	16.91	16.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
ACAD ACADIA Pharmaceuticals	96.71%
MRUS Merus	96.14%
RNA Avidity Biosciences	N/A

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.90%
ACAD ACADIA Pharmaceuticals	26.50%
MRUS Merus	4.57%
RNA Avidity Biosciences	3.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	298.42 million	212.18 million	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	123.01 million	Optionable
MRUS Merus	37	69.21 million	66.05 million	Optionable
RNA Avidity Biosciences	190	120.52 million	115.90 million	Optionable

ABCL, ACAD, MRUS, and RNA Headlines

Recent News About These Companies

Wolfe Research Begins Coverage on Avidity Biosciences (NASDAQ:RNA)

June 19 at 1:43 AM | americanbankingnews.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Kathleen P. Gallagher Sells 911 Shares

June 18 at 8:52 PM | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Trading Up 4.1% - Here's Why

June 17 at 1:35 PM | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Coverage Initiated at Wolfe Research

June 17 at 8:43 AM | marketbeat.com

Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential

June 16 at 9:12 PM | investing.com

Avidity Biosciences (NASDAQ:RNA) Shares Down 3.5% - Here's What Happened

June 16 at 4:45 PM | marketbeat.com

Assenagon Asset Management S.A. Increases Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)

June 15, 2025 | marketbeat.com

Rhumbline Advisers Increases Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)

June 14, 2025 | marketbeat.com

GAMMA Investing LLC Has $1.96 Million Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

June 14, 2025 | marketbeat.com

Leerink Partnrs Analysts Decrease Earnings Estimates for RNA

June 14, 2025 | americanbankingnews.com

W. Michael Flanagan Sells 20,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock

June 12, 2025 | marketbeat.com

Leerink Partnrs Has Pessimistic View of RNA FY2026 Earnings

June 12, 2025 | marketbeat.com

Raymond James Initiates Coverage of Avidity Biosciences (RNA) with Strong Buy Recommendation

June 12, 2025 | msn.com

Barclays Forecasts Strong Price Appreciation for Avidity Biosciences (NASDAQ:RNA) Stock

June 12, 2025 | americanbankingnews.com

Avidity Biosciences (NASDAQ:RNA) Stock Price Expected to Rise, Citigroup Analyst Says

June 12, 2025 | americanbankingnews.com

Analysts Offer Predictions for RNA FY2026 Earnings

June 12, 2025 | americanbankingnews.com

Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James

June 11, 2025 | msn.com

Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress

June 11, 2025 | prnewswire.com

Cantor Fitzgerald Weighs in on RNA FY2026 Earnings

June 11, 2025 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Coverage Initiated by Analysts at Raymond James

June 11, 2025 | marketbeat.com

JPMorgan Chase & Co. Issues Positive Forecast for Avidity Biosciences (NASDAQ:RNA) Stock Price

June 11, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL, ACAD, MRUS, and RNA Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$3.47 +0.35 (+11.22%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$3.48 +0.01 (+0.43%)

As of 06/18/2025 07:59 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

ACADIA Pharmaceuticals NASDAQ:ACAD

$22.95 +0.15 (+0.66%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$22.94 -0.01 (-0.05%)

As of 06/18/2025 07:57 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Merus NASDAQ:MRUS

$52.59 -0.49 (-0.92%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$52.58 -0.01 (-0.02%)

As of 06/18/2025 06:25 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Avidity Biosciences NASDAQ:RNA

$29.32 -0.04 (-0.14%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$29.06 -0.27 (-0.90%)

As of 06/18/2025 07:11 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time